Grand Rapids applied for — and was denied — an exemption for its 'Thunderhawks' mascot, and has pushed back against what it ...

Oppenheimer notes that Gilead (GILD) shares are weak today following reports from multiple media outlets that the Health and Human Services ...

JPMorgan says that while the Wall Street Journal’s report on potential Centers for Disease Control and Prevention funding cuts for HIV ...

Gilead Sciences, Inc. today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment portfolio and pipeline at the Conference on Retroviruses ...

Gilead is set to launch a Phase III trial of its once-yearly lenacapavir pre-exposure prophylaxis (PrEP) for human ...

The right prep school will instil in a child a lifetime love of learning and a bedrock of skills, qualities and values that will take them through to secondary school and beyond. The best UK prep ...

Gilead (NASDAQ:GILD) on Tuesday announced encouraging ... as two once-yearly formulations for pre-exposure prophylaxis (PrEP) in HIV prevention. The company said that the median plasma ...

But only 3.5 million take pre-exposure prophylaxis (PrEP), which reduces a person ... found that a yearly injection lenacapavir, made by Gilead Sciences, was “safe and well tolerated”.

Gilead said two ex­per­i­men­tal once-a-year ver­sions of its HIV pre­ven­tion shot lenaca­pavir passed muster in an ear­ly-stage study with a small group of healthy par­tic­i­pants … ...

After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the drug has shown promise being dosed even further apart at only once a year.

Last year, Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against infection with just a single injection every six months.